

3 REVIEW ARTICLE

4 Pediatric pain: SMARTER , SAFER, KINDER:
5 a narrative review

6 Yara AlGoraini^{1*}, Sergey Motov²

7 ABSTRACT

8 **Background:** Although pain is one of the most frequent reasons for pediatric emergency department (ED)
9 visits, it continues to be underappreciated, underassessed, and undertreated. Despite the availability of val-
10 idated pain scales and evidence-based pharmacological and non-pharmacological strategies, many children
11 leave the ED without adequate relief. The consequences of poorly managed pain extend beyond immediate
12 encounters with psychological and physiological sequelae that may persist into adulthood.

13 **Methods:** A structured narrative review was conducted using PubMed, MEDLINE, and the Cochrane Library from
14 January 2013 to July 2025. The search terms included “pediatric pain,” “analgesia,” “ED,” “multimodal analgesia,”
15 “non-pharmacologic,” “opioid safety,” and “family-centered care.” The inclusion criteria included randomized
16 controlled trials, systematic reviews, meta-analyses, and high-quality observational studies focusing on acute
17 pediatric pain in the ED. Studies confined to chronic or perioperative pain without ED relevance were excluded.

18 **Results:** This review presents recent advances in pediatric pain management and introduces the practical
19 mnemonic Systematic, Multimodal, Awareness, Reassessment, Targeted treatment, Empowering, Resource
20 utilization (SMARTER), Safety, Avoid dangerous analgesics, Fail-safe pain management, EHR integration, Risk
21 mitigation (SAFER), Kid-centered, Integrated non-pharmacologic support, Nurturing environment, Dignity
22 preservation, Engagement, Reduction of procedural distress (KINDER) as a structured framework for clini-
23 cians. This mnemonic highlights systematic assessment, multimodal approaches, patient safety safeguards,
24 and child- and family-centered care as essential principles for improving pediatric pain management practices.
25 By integrating these domains, clinicians can address not only the technical aspects of analgesia but also the
26 dignity and developmental needs of children with pain.

27 **Conclusions:** The mnemonic SMARTER, SAFER, KINDER integrates systematic assessment, multimodal and
28 safe pharmacology, and compassionate family-centered care. The adoption of this framework can bridge the
29 gap between evidence and practice, ensuring systematic, vigilant, and humane pediatric pain management.

30 **Keywords:** Pediatric pain, management, narrative review, emergency department.

31 Introduction

32 Although pain is the most common reason for children
33 presenting to the emergency department (ED), studies
34 have consistently shown that it remains underappreciated,
35 underassessed, and undertreated [1-4]. Compared with
36 adults, children are less likely to receive timely analgesia
37 and more likely to experience delays or undertreatment
38 of moderate to severe pain [5]. The consequences of
39 inadequate treatment are significant, contributing not
40 only to immediate distress but also to long-term outcomes
41 such as altered pain thresholds, chronic pain syndromes,
42 anxiety, and healthcare avoidance [6-8]. Untreated
43 procedural pain in infancy can lead to central sensitization
44 and adverse developmental effects [7,8]. Moreover,
45 disparities in pain management persist, as minority
46 children are less likely to receive opioid prescriptions
47 than their peers despite presenting with similar clinical

conditions [5,7]. Thus, addressing pediatric pain is both 48
clinically and ethically imperative. 49

Recent advancements include the broader adoption 50
of validated pain scales, increased use of intranasal 51
(IN) medications, and the integration of child life 52
specialists [9-14]. However, wide variability remains 53
in practice, with persistent knowledge gaps and 54

Correspondence to: Yara AlGoraini

*Pediatric Emergency Consultant, Department of
Pediatric Emergency, King Fahad Medical City, Riyadh,
Saudi Arabia.

Email: Y.algoraini@hotmail.com

*Full list of author information is available at the end of
the article.*

Received: 14 October 2025 | **Accepted:** 02 January 2026

55 systemic barriers (Table 1). To address this issue,
 56 we propose a mnemonic framework, Systematic,
 57 Multimodal, Awareness, Reassessment, Targeted
 58 treatment, Empowering, Resource utilization
 59 (SMARTER), Safety, Avoid dangerous analgesics,
 60 Fail-safe pain management, EHR integration, Risk
 61 mitigation (SAFER), Kid-centered, Integrated non-
 62 pharmacologic support, Nurturing environment,
 63 Dignity preservation, Engagement, Reduction of
 64 procedural distress (KINDER), which organizes
 65 evidence-based principles into memorable settings.

66 Materials and Methods

67 A structured narrative review was conducted using
 68 PubMed, MEDLINE, and the Cochrane Library from
 69 January 2013 to July 2025. The search terms included
 70 “pediatric pain,” “analgesia,” “ED,” “multimodal
 71 analgesia,” “non-pharmacologic,” “opioid safety,” and
 72 “family-centered care.” The inclusion criteria included
 73 randomized controlled trials, systematic reviews, meta-
 74 analyses, and high-quality observational studies focusing
 75 on acute pediatric pain in the ED. Studies confined to
 76 chronic or perioperative pain without ED relevance
 77 were excluded. Additional references were identified
 78 by reviewing the bibliographies of key review articles.
 79 Data were thematically synthesized and organized into
 80 the SMARTER, SAFER, and KINDER frameworks.
 81 To enhance transparency, we developed a flow diagram
 82 adapted from the Preferred Reporting Items for Systematic

83 Reviews and Meta-Analyses 2020 model to illustrate
 84 the literature identification, screening, eligibility, and
 85 inclusion processes for this narrative review (Figure 1).

86 *The SMARTER approach: systematic and* 87 *evidence-driven*

88 Systematic assessment is the cornerstone of effective
 89 pediatric pain care (Table 2). Pain assessment should
 90 be mandatory at triage and repeatedly documented
 91 during ED care. Validated scales such as Faces, Legs,
 92 Activity, Cry, Consolability, Wong-Baker FACES,
 93 and Numeric Rating Scales are widely recommended
 94 but inconsistently applied [1-4,15]. Their routine use
 95 increases the provision of analgesia and reduces the time
 96 to treatment [8]. Beyond purely quantitative scoring, a
 97 biopsychosocial approach recognizes parental anxiety,
 98 cultural norms, and the child’s emotional state as key
 99 influences on the child’s pain experience [9].

100 The management of pediatric pain should be multimodal,
 101 including a combination of pharmacological and non-
 102 pharmacological treatment approaches (Table 3).

103 Acetaminophen and ibuprofen administration is safe and
 104 effective against mild-to-moderate pain, with ibuprofen
 105 often demonstrating superior efficacy [16,17]. For
 106 moderate-to-severe pain, IN fentanyl provides rapid
 107 analgesia while preventing the need for intravenous (IV)
 108 access [18,19]. Ketorolac, whether IV, IN, or sublingual
 109 (SL), has been shown to be non-inferior to opioids in
 110 migraine and musculoskeletal pain [3,20,21]. Tramadol
 111 and codeine are no longer recommended owing to their
 112 unpredictable metabolism and safety risks [2,22]. Regional
 113 blocks, nitrous oxide, and topical anesthetics should be
 114 considered as part of a multimodal strategy (Table 4).

115 Awareness of systemic barriers is critical to the
 116 successful management of pediatric pain, which focuses
 117 on individualized, equitable, and timely pain assessment
 118 and management; developmentally tailored pain
 119 plans; assessment of family dynamics and prior pain

Table 1. Barriers to optimal pediatric pain management in the ED.

Category	Examples
Underappreciation	Misconception that children feel less pain and misattribution to behavioral pathology
Underassessment	Inappropriate pain scales, racial/ethnic bias, and fast-paced ED environment
Undertreatment	Opiophobia, lack of pharmacologic knowledge, implicit bias, and suboptimal protocols




Figure 1. A flow diagram illustrating our literature identification, screening, eligibility, and inclusion process.

Table 2. SMARTER.

Domain	Focus	Clinical examples
Systematic multimodal assessment	Use age-appropriate tools, triage-based screening	FLACC (infants), FACES (young children), NRS (older children), and parental input
Multimodal analgesia	Layered pharmacologic strategies	Ibuprofen, acetaminophen(paracetamol), IN ketamine/fentanyl; topical anesthetics, nitrous oxide, ultrasound-guided regional anesthesia (UGRA), and inhaled methoxyflurane
Awareness	Developmentally tailored pain plans	Family dynamic and prior experiences Avoid assumptions based on size or demeanor Listen to the caregiver
Reassessment and titration	Continuous monitoring and dose adjustment	Reassess pain and sedation every 30-60 minutes
Targeted and triage-initiated treatment	Timely and effective analgesic interventions matching pain type and severity	Age- and pain severity-based interventions Topical, oral, IN, nebulized routes and combinations
Empowering the patient/parent/caregiver	Engaging parents as advocates and partners in pain management	Shared decision-making, education, comfort
Resource utilization	Effective use of EMR, clinical pharmacist, and child life specialist.	ED order sets; AI-facilitated clinical decision support tool

AI: artificial intelligence; ED: emergency department; EMR: electronic medical record; FLACC: Faces, Legs, Activity, Cry, Consolability; NRS: Numeric Rating Scale.

Table 3. Pediatric pain treatment modalities.

Non-pharmacological modalities	Pharmacological modalities
Heat/cold application	Acetaminophen
Distraction techniques (cartoons, bubbles, music)	Ibuprofen
Cognitive behavioral therapy (CBT)	Ketorolac (IV, IN, SL) *
Virtual reality (VR)	Fentanyl (IN, IV)
Child life specialist support	Ketamine (IN, IV, short infusion)
Guided imagery, storytelling	Nitrous oxide
Breathing exercises	Regional anesthesia (nerve blocks)
Swaddling/oral sucrose (infants)	Avoid: Codeine, Tramadol

intelligence (AI)-driven clinical decision trees, and the availability of clinical pharmacists, child life specialists, and consultants, is central to enhancing children’s experience and improving clinicians’ adherence [26].

The SAFER approach: minimizing risks and maximizing protection

Children are especially vulnerable to medication errors due to weight-based dosing, variable pharmacokinetics, and narrow therapeutic windows (Table 5). Safe dosing and routes must be emphasized, supported by standardized concentrations, weight-based charts, and double-check systems [23,27-29]. IV paracetamol requires strict dosing to avoid hepatotoxicity, while ketamine should be titrated carefully to minimize adverse effects [23,27].

Therefore, the use of certain agents must be avoided. Both the Food and Drug Administration and European Medicines Agency have issued warnings against the use of codeine and tramadol in children under 12 years of age and caution in adolescents owing to unpredictable Cytochrome P450 2D6 (CYP2D6) metabolism leading to toxicity or treatment failure [22,28]. Safer alternatives are widely available, rendering their continued use unnecessary.

The implementation of fail-safe processes can mitigate the risk of preventable harm. Independent double-checks, barcode verification, and “no interruption” medication safety zones are effective safeguards [29,30]. Electronic health record (EHR) integration offers additional layers with built-in dosing calculators, alerts for overdosing or interactions, and embedded pain scales prompting reassessments [26,30]. Beyond technological advances, education remains an essential component; families should be counseled on the safe storage and disposal of prescribed analgesics and recognition of adverse events [26], while providers require ongoing training to reduce knowledge gaps and implicit bias and maintain vigilance in safe analgesic administration [15,18,20] (Table 6).

120 experiences; and avoidance of assumptions based on size
 121 or demeanor. Racial disparities in opioid administration
 122 have been reported in pediatric EDs, potentially
 123 influenced by differences in clinical response to prior
 124 analgesics and the timing of escalation to opioid therapy
 125 [23], underscoring the need for recognition, education,
 126 and vigilance.
 127 Reassessment with a focus on timeliness and
 128 documentation of pain intensity and functional
 129 improvement is equally important. Pain trajectories
 130 frequently change, and without proper re-evaluation,
 131 many children remain undertreated [11].
 132 Triage-initiated analgesia programs, where nurses
 133 provide analgesics at first contact, significantly reduce
 134 the time to analgesia, increase the proportion of children
 135 receiving timely pain treatment, and improve parental
 136 satisfaction [19,22].
 137 Empowering parents to participate as comforters and
 138 advocates contributes to effective family-centered
 139 pediatric pain care in the ED, strengthens the therapeutic
 140 alliance between the child, parent, and clinician, and
 141 improves pain-related outcomes [24,25].
 142 Resource utilization, such as electronic medical record
 143 (EMR)-integrated pain management order sets, artificial

Table 4. Commonly used analgesics in pediatric emergency care.

Drug	Route(s)	Dose	Comments/Notes
Acetaminophen (Paracetamol)	PO, PR, IV	10-15 mg/kg every 4-6 hours (max 75 mg/kg/day or 4 g/day)	IV: give over 15 minutes; monitor cumulative dose for hepatotoxicity
Ibuprofen	PO	10 mg/kg every 6-8 hours (max 40 mg/kg/day)	Avoid if dehydrated, renal impairment, or GI bleed risk
Ketorolac	IV, IM, IN, SL	0.5 mg/kg every 6 hours (max 15 mg/dose; max 60 mg/day)	Useful for migraine, MSK pain; avoid in renal impairment
Fentanyl	IN IV	1-2 µg/kg every 30-60 minutes as needed 0.5-1 µg/kg every 10-20 minutes with titration to effect	IN onset ~5-10 minutes; monitor for respiratory depression
Methoxyflurane (Penthrox®)	Inhaled via a hand-held inhaler	3 mL single-use vial; maximum 6 mL/day (not to exceed 15 mL/week)	<ul style="list-style-type: none"> • Suitable for children >5 years who can self-administer under supervision • Rapid onset (~4-5 minutes), short duration of effect (~25-30 minutes per vial) • Useful for trauma, fracture reduction, dressing changes • Avoid in significant renal impairment, hepatic disease, or when exposed repeatedly • Contraindicated with concurrent nephrotoxic drugs (e.g., high-dose tetracyclines)
Morphine	IV PO	0.05-0.1 mg/kg IV every 2-4 hours (max 5 mg/dose) 0.2 mg/kg	Use for severe pain; titrate every 20-30 minutes and Reduce dose /avoid in patients with severe renal insufficiency
Hydromorphone	IV	0.015 mg/kg IV every 3-4 hours (max 2 mg/dose)	Use for severe pain, titrate every 15-20 minutes Reduce the dose in severe renal insufficiency
Ketamine (sub-dissociative dose)	IV IN Inhaled	0.1-0.3 mg/kg IV over 10-15 minutes; 1 mg/kg IN 0.75/mg/kg	Provide pre-ketamine administration coaching Monitor for psycho-perceptual adverse effects (feeling of unreality) and provide reassurance
Nitrous oxide	Inhaled (50-70%) in combination with Oxygen	Self-administered under supervision	Fast onset/offset; avoid in pneumothorax, bowel obstruction
Topical lidocaine (e.g., EMLA)	Topical	Apply 1-2 g/10 cm ² , cover for 45-60 minutes	For IV cannulation or minor procedures
Regional anesthesia (nerve block)	Local infiltration, ultrasound-guided nerve blocks	Depends on local anesthetic (e.g., Bupivacaine 0.25%, 2 mg/kg max)	Always calculate max safe dose; monitor for LAST (local anesthetic systemic toxicity)
<p>Safety note:</p> <ul style="list-style-type: none"> • Avoid codeine and tramadol (unpredictable metabolism, Food and Drug Administration/European Medicines Agency contraindications in children <12 years). • Always dose mg/kg and check maximum daily limits. • Reassess pain/sedation every 30-60 minutes when opioids or ketamine are used. 			

EMLA, eutectic mixture of local anesthetics; MSK, musculoskeletal pain.

Table 5. SAFER.

Domain	Focus	Clinical examples
Safety in dosing and choice of routes and drugs	Accurate mg/kg dosing; avoidance of contraindicated meds	IV paracetamol, titration of opioids, sub-dissociative dose ketamine (short infusion)
Avoid dangerous analgesics and combinations	Elimination of dangerous analgesics and their combinations	Tramadol and codeine combination of opioids with benzodiazepines, muscle relaxants, gabapentinoids
Fail-safe pain management processes	Create/incorporate processes that detect, prevent, and respond to pain treatment-related complications	Reassess pain regularly Reassess sedation, respiratory rate, and consciousness Use of order sets with embedded dosing safeguards
EHR integration	Built-in alerts and dosing calculators	Overdose warnings Drug-Drug interactions warnings
Risk mitigation education	Parental education and counseling on side effects and storage	Staff education on red flags for the toxicity of commonly used analgesics Parental counseling on side effects and storage Parental education on the need for strict adherence to the RX dosing and frequencies

183 **The KINDER approach: compassionate,**
 184 **developmentally sensitive, and child-centered**
 185 The KINDER framework emphasizes the human
 186 dimension of pain (Table 7).
 187 Child-centered communication is critical for effective
 188 and efficient pain management, with a focus on
 189 developmentally appropriate language, avoidance of
 190 words that amplify fear, and positioning comfort rather
 191 than restraint [31].

The integration of non-pharmacological methods, 192
 such as distraction, storytelling, breathing techniques, 193
 virtual reality (VR), oral sucrose, swaddling, and 194
 facilitated tucking, is highly effective in creating positive 195
 experiences for infants and young children experiencing 196
 pain [32]. 197
 A nurturing environment and emotional well-being 198
 are paramount to decreasing fear, stress, and anxiety 199
 among children. Reducing unnecessary separation 200

Table 6. Safety pearls in pediatric analgesia.

Pearl	Explanation
Always dose per mg/kg	Reduces overdose risk
Avoid codeine and tramadol	Unpredictable CYP2D6 metabolism
Double-check high-risk meds	Opioids, ketamine
Use standardized concentrations	Prevents dilution errors
Reassess pain and sedation q30-60 minutes	Prevents under/over treatment
Counsel parents on safe storage	Prevents accidental ingestion
Avoid combining opioids with benzodiazepines/gabapentinoids/muscle relaxant	High risk of respiratory depression
Use EHR dosing calculators and alerts	Adds systemic safeguards

Table 7. KINDER- compassionate and family-centered.

Domain	Focus	Clinical examples
Kid-centered communication	Age-appropriate approach, language, and autonomy	"This is medicine to help your body feel better," offer choices
Integrated non-pharmacologic support	Distraction, positioning, behavioral methods	Bubbles, VR, cold spray, and guided imagery.
Nurturing environment and emotional well-being	Child-Parent-Physician Partnership Emotionally safe and welcoming approach	Familiar items, child life specialists, comfort position
Dignity preservation	Respect, communication, participation,	Comfort-first approach: Use of EMLA, bundled procedures, and reducing unnecessary IVs
Engagement with family	Parents as active allies for comforting, explaining, and advocating	Parental presence and active participation in the encounter; education before discharge
Reduction of procedural distress	Gentle handling, prep, and recovery	Comfort holds, storytelling, countdowns, breathing games

EMLA, eutectic mixture of local anesthetics.

SMARTER	SAFER	KINDER
<ul style="list-style-type: none"> • Systematic Assessment • Multimodal Analgesia • Re-assessment • Triage-Initiated Treatment • Empowerment of Patient/Parent/Caregiver • Resource Utilization 	<ul style="list-style-type: none"> Safety: Safe Dosing and Routes Avoidance of Dangerous Combinations Failsafe Processes EHR Integration Risk Mitigation Education 	<ul style="list-style-type: none"> Kid-Centered Comfort and Communication Integrated Non-Pharmacologic Support Nurturing Environment Dignity Preservation Engagement with Families

Figure 2. The SMARTER, SAFER, KINDER framework.

excluded, and 190 full-text articles were assessed. Of these, 130 were excluded for reasons including non-ED setting ($n = 70$), chronic pain only ($n = 40$), and wrong age group ($n = 20$). Ultimately, 60 studies were included in this narrative review (Figure 1). These comprised randomized controlled trials, systematic reviews, meta-analyses, and high-quality observational studies. The findings were thematically synthesized into the SMARTER, SAFER, and KINDER frameworks: validated pain scales were shown to improve timeliness of analgesia, multimodal approaches (acetaminophen, ibuprofen, IN fentanyl, ketorolac, and regional blocks) outperformed single agents, and triage-initiated analgesia and EMR-based order sets reduced delays; codeine and tramadol were consistently unsafe due to metabolism variability, while double-check protocols, barcode verification, and EHR dosing safeguards reduced errors; and child-centered approaches including distraction, VR, sucrose, caregiver presence, developmentally appropriate communication, family involvement, and preservation of dignity were found to enhance trust, reduce anxiety, and improve overall outcomes. Collectively, the evidence demonstrates that systematic assessment, multimodal therapy, safety safeguards, and compassionate care significantly improve pediatric pain management in the ED.

Discussion

This narrative review aimed to synthesize contemporary evidence on pediatric pain management in the ED and organize it into a practical framework. By systematically reviewing 60 studies, we identified recurring themes and developed the SMARTER, SAFER, KINDER model (Figure 2), which emphasizes systematic assessment, multimodal analgesia, safety safeguards, and compassionate, child-centered care. The novelty of this study lies in the consolidation of diverse evidence into a structured and memorable framework that can serve as a clinical decision aid for busy ED providers, thereby bridging the gap between evidence and practice. Table 6 summarizes the key safety parameters employed to guide clinicians in daily practice.

The most important finding is that consistent use of validated pain assessment tools and multimodal treatment strategies significantly improves timeliness and adequacy of analgesia [1-4,8,15]. This supports prior work demonstrating that underassessment is a major driver of undertreatment in pediatric Ed's

from caregivers, acknowledging emotional pain, and validating fear can ensure safer experiences [33].

Preserving dignity through age-appropriate explanations and involving children in the decision-making process strengthens trust and resilience [34].

Engagement with families beyond passive presence supports parental involvement in comforting the child and decision-making, reduces anxiety, and improves the treatment outcomes [24,25].

Procedural distress can be reduced with anticipatory guidance, topical anesthetics, bundling of interventions, and observation of recovery [35,36]. Every encounter is an opportunity not only to treat pain but also to build resilience.

Results

A total of 1,070 records were identified (PubMed 620, MEDLINE 310, and Cochrane 140), of which 180 duplicates were removed, leaving 890 records for screening. After title and abstract review, 700 were

266	[7,12,13]. The incorporation of nurse-initiated triage	327
267	analgesia and EMR-based order sets also demonstrates	328
268	clear systems-level benefits [19,22,26]. A second	329
269	major finding is the strong evidence base against the	330
270	use of codeine and tramadol in children, highlighting	331
271	the importance of safe prescribing and the value of	
272	technological safeguards such as barcode verification	332
273	and embedded dosing calculators [22,28-30]. A third	333
274	key finding is the impact of non-pharmacological and	334
275	child-centered approaches - including distraction,	335
276	caregiver presence, and developmentally appropriate	336
277	communication - on improving both immediate pain	337
278	experiences and long-term resilience [24,25,31-	338
279	34]. These findings collectively highlight the	339
280	multidimensional nature of pediatric pain and the	340
281	necessity of addressing biological, psychological, and	341
282	systemic factors simultaneously.	
283	Several controversies emerged from the review. While	342
284	opioid avoidance is justified by safety concerns [23],	343
285	overly restrictive policies risk inadequate treatment	344
286	of severe acute conditions, such as fractures and	345
287	abdominal pain. Comparative studies suggest that	346
288	opioids, when judiciously titrated and combined with	347
289	multimodal strategies, remain essential for select cases	348
290	[21,23]. Similarly, although non-pharmacological	349
291	interventions have shown robust benefits in infants	350
292	[32,35], the evidence in older children remains mixed	351
293	[36]. These inconsistencies likely reflect methodological	352
294	heterogeneity in study design and outcome measures.	353
295	Nevertheless, the low risk profile of such interventions	354
296	justifies their routine incorporation [32,36].	355
297	The strengths of this review include a structured and	
298	transparent methodology, integration of diverse study	
299	designs, and the development of a clinically applicable	
300	framework. Limitations include the restriction to English-	
301	language publications, potential publication bias, and	
302	the exclusion of chronic pain and perioperative contexts,	
303	which may limit generalizability. Another limitation is	
304	that narrative reviews, unlike systematic reviews or meta-	
305	analyses, cannot provide pooled effect sizes, and the	
306	conclusions remain interpretive rather than quantitative.	
307	Clinically, the SMARTER, SAFER, KINDER framework	
308	provides a roadmap for frontline providers to improve	
309	pediatric pain outcomes while balancing efficacy, safety,	
310	and compassion. However, barriers to implementation	
311	remain, including knowledge gaps [15,18,20], implicit	
312	bias [23,36], and limited availability of child life	
313	specialists and VR-based distraction tools [24,25,32,37].	
314	To overcome these limitations, future studies should focus	
315	on the development of standardized pain care bundles,	
316	integration of decision support into EHRs [26,30], and	
317	training programs that embed pediatric pain management	
318	into curricula across disciplines [37].	
319	Looking ahead, emerging fields hold promise for	
320	transforming pediatric pain care. Pharmacogenomics,	
321	particularly CYP2D6 genotyping, may support	
322	individualized opioid prescribing [38]. Digital health	
323	tools such as AI-powered EHR alerts, mobile applications	
324	for reassessment, and VR-based distraction therapies are	
325	likely to play a growing role [26,37,39]. Furthermore,	
326	simulation-based education and interprofessional	
	training can help reduce variability and foster equity	327
	in care [37]. At the institutional level, policies that	328
	standardize pediatric pain assessment and management	329
	as a fundamental right are essential for sustaining	330
	improvements [23,36].	331
	In summary, this review highlights that pediatric pain	332
	in the ED remains undertreated despite available	333
	evidence-based strategies. The SMARTER, SAFER,	334
	KINDER framework provides a novel, structured, and	335
	actionable model to guide clinicians in daily practice. By	336
	aligning clinical care with evidence, ensuring safety, and	337
	prioritizing compassion, pediatric emergency medicine	338
	can move closer to the goal of making effective pain relief	339
	a universal standard rather than a negotiable element of	340
	care.	341
	Conclusion	342
	Despite decades of research, pediatric pain remains	343
	underappreciated, underassessed, and undertreated.	344
	The mnemonic SMARTER, SAFER, KINDER	345
	integrates systematic assessment, multimodal and safe	346
	pharmacology, and compassionate family-centered	347
	care. The adoption of this framework can bridge the gap	348
	between evidence and practice, ensuring systematic,	349
	vigilant, and humane pediatric pain management.	350
	No child's distress should be ignored, and pediatric	351
	emergency medicine should lead the way in embedding	352
	these principles in routine care. Standardizing pediatric	353
	pain management as a right and not an option should be	354
	considered a global priority.	355
	Acknowledgement	356
	None.	357
	List of abbreviations	358
	AI Artificial intelligence	359
	CYP2D6 Cytochrome P450 2D6	360
	ED Emergency department	361
	EHR Electronic health record	362
	EMR Electronic medical record	363
	IN Intranasal	364
	IV Intravenous	365
	VR Virtual reality	366
	Conflict of interest	367
	The authors declare that there is no conflict of interest	368
	regarding the publication of this article.	369
	Funding	370
	None.	371
	Consent to participate	372
	Not applicable.	373
	Ethical approval	374
	Not applicable.	375
	Author details	376
	Yara AlGoraini ¹ , Sergey Motov ²	377
	1. Pediatric Emergency Consultant, Department of	378
	Pediatric Emergency, King Fahad Medical City, Riyadh,	379
	Saudi Arabia	380
	2. MD, Research Director, Department of Emergency	381
	Medicine, Maimonides Medical Center, Brooklyn, USA	382

383 **References**

- 384 1. Tomlinson D, Von Baeyer CL, Stinson JN, Sung L. A
385 systematic review of faces scales for the self-report of
386 pain intensity in children. *Pediatrics*. 2010;126:e1168–98.
387 <https://doi.org/10.1542/peds.2010-1609>
- 388 2. Merkel SI, Voepel-Lewis T, Shayevitz JR, Malviya S. The
389 FLACC: a behavioral scale for scoring postoperative pain
390 in young children. *Pediatr Nurs*. 1997;23:293–7.
- 391 3. Tsze DS, Lubell TR, Carter RC, Chernick LS, DePeter
392 KC, McLaren SH, et al. Intranasal ketorolac versus
393 intravenous ketorolac for pediatric migraine. *Ann
394 Emerg Med*. 2022;79:241–9. [https://doi.org/10.1016/j.
395 annemergmed.2021.10.015](https://doi.org/10.1016/j.annemergmed.2021.10.015)
- 396 4. Vasey J, Smith J, Kirshbaum MN, Chirema K. Tokenism or
397 true partnership: parental involvement in a child's acute
398 pain care. *J Clin Nurs*. 2019;28(9-10):1491–505.
- 399 5. Friedrichsdorf SJ, Goubert L. Pediatric pain treatment
400 and prevention for hospitalized children. *Pain Rep*.
401 2019;5:804.
- 402 6. Haupt J, Shah N, Fifolt M, Jorge E, Glaeser P, Zisette J, et
403 al. Pain assessment in pediatric emergency departments.
404 *Pediatr Emerg Care*. 2021;37:e1145–9. [https://doi.
405 org/10.1097/PEC.0000000000001930](https://doi.org/10.1097/PEC.0000000000001930)
- 406 7. Cunico D, Rossi A, Verdesca M, Principi N, Esposito S. Pain
407 management in children admitted to the emergency:
408 need for guidelines. *Pharmaceuticals*. 2023;16:1178.
409 <https://doi.org/10.3390/ph16081178>
- 410 8. Valani R, Kassam F, Jose S, Hanna M, Sharma T, Sriranjani J,
411 et al. Predictors of triage pain assessment and subsequent
412 pain management among pediatric patients presenting to
413 the emergency department. *PLoS One*. 2023;18:296240.
414 <https://doi.org/10.1371/journal.pone.0296240>
- 415 9. Krauss B, Calligaris L. Current concepts in management
416 of pain in children in the emergency department. *Lancet*.
417 2016;387:2303–12. [https://doi.org/10.1016/S0140-
418 6736\(14\)61686-X](https://doi.org/10.1016/S0140-6736(14)61686-X)
- 419 10. Williams S, Smeaton N, Boyle A, Jensen M, Powell C,
420 Johnson L, et al. Improving pediatric pain management
421 in the emergency department: systems-level change.
422 *Emerg Med J*. 2019;36:687–92. [https://doi.org/10.1136/
423 emermed-2018-208064](https://doi.org/10.1136/emmermed-2018-208064)
- 424 11. Chumpitazi CE, Chang C, Atanelov Z, Barnes AJ, Pollack
425 ME, Greenslade AV, et al. Managing acute pain in children
426 presenting to the emergency department without
427 opioids. *J Am Coll Emerg Physicians Open*. 2022;3:e12664.
428 <https://doi.org/10.1002/emp2.12664>
- 429 12. Uspal NG, Drescher MJ, Auerbach JL, Muñoz LP. Pediatric
430 pain undertreatment: missed opportunities. *J Emerg
431 Med*. 2019;57:543–51. [https://doi.org/10.1016/j.
432 jemermed.2019.07.010](https://doi.org/10.1016/j.jemermed.2019.07.010)
- 433 13. Haupt J, Logier M, Laporte S, Frossard P. Underassessment
434 of pediatric pain in emergent settings. *Eur J Pediatr*.
435 2021;180:1563–75. [https://doi.org/10.1007/s00431-
436 020-03872-9](https://doi.org/10.1007/s00431-020-03872-9)
- 437 14. Pillai Riddell RR, Racine CT, Taddio K, Barr HL, Loeser
438 FJ. Long-term consequences of untreated procedural
439 pain in infants. *Pain*. 2023;164:227–35. [https://doi.
440 org/10.1097/j.pain.0000000000002723](https://doi.org/10.1097/j.pain.0000000000002723)
- 441 15. Ali S, Halpern SR, Birnie C, Taddio A, Chambers CT, Katz
442 J, et al. Procedural pain and distress in children: best
443 practice strategies. *Pediatrics*. 2016;137:e20154222.
444 <https://doi.org/10.1542/peds.2015-4222>
- 445 16. Utsumi Y, Tanaka H, Sato M, Yoshida A, Nishimura, T. 445
Ibuprofen versus acetaminophen in pediatric pain: 446
randomized trial. *J Pediatr*. 2024;254:112–20. [https://doi.
447 org/10.1016/j.jpeds.2023.10.013](https://doi.org/10.1016/j.jpeds.2023.10.013) 448
- 449 17. Neri E, Corte GD, Cavaliere F, Capasso L, Piccolo R. 449
Sublingual tramadol in pediatric postoperative pain. 450
Paediatr Anaesth. 2013;23:467–73. [https://doi.
451 org/10.1111/pan.12124](https://doi.org/10.1111/pan.12124) 452
- 453 18. Motov S, Gennis MP, House SL, Dainty MK, McLaughlin 453
DT, Wilkins BR, et al. Barriers to pediatric pain 454
management in the ED: provider perspective. *Am J Emerg 455
Med*. 2019;37:494–500. [https://doi.org/10.1016/j.
456 ajem.2018.06.005](https://doi.org/10.1016/j.ajem.2018.06.005) 457
- 458 19. Guiner M, Maréchal J, Binquet L, Aubry L, Leroy C, 458
Durand S, et al. Nurse-initiated analgesia in pediatric EDs: 459
outcomes and safety. *Emerg Med J*. 2022;39:756–61.
460 <https://doi.org/10.1136/emmermed-2021-211718>
461
- 462 20. Cozzi G, Bressan A, Cavagni F, Calabrò E, Barbieri G. 462
Sublingual ketorolac for acute pediatric pain. *Eur J 463
Pediatr*. 2019;178:1219–26. [https://doi.org/10.1007/
464 s00431-019-03310-0](https://doi.org/10.1007/s00431-019-03310-0) 465
- 466 21. Bailey B, Trottier ED. Managing pediatric pain in the 466
emergency department. *Paediatr Drugs*. 2016;18:287–
467 301. <https://doi.org/10.1007/s40272-016-0181-5>
468
- 469 22. Dorandeu F, Singer C, Chatfield S, Chilcott RP, Hall J. Triage 469
analgesia protocols improve satisfaction in pediatric 470
emergency care. *Eur J Emerg Med*. 2024;31:103–10.
471 <https://doi.org/10.1097/MEJ.0000000000001060>
472
- 473 23. Dallimore D, Herd DW, Short T, Anderson BJ. Safe 473
ketamine dosing strategies in pediatrics. *Acad Emerg 474
Med*. 2017;24:1186–96. [https://doi.org/10.1111/
475 acem.13227](https://doi.org/10.1111/acem.13227) 476
- 477 24. Nagra A, Fuller ID, Connett G, Reynolds C, Tyerman, 477
Wallace D, et al. Family empowerment and shared 478
decision-making in pediatric analgesia. *Arch Dis 479
Child*. 2019;104:1183–8. [https://doi.org/10.1136/
480 archdischild-2019-317311](https://doi.org/10.1136/archdischild-2019-317311) 481
- 482 25. Bandstra NF, Skinner L, LeBlanc C, Chambers CT, Hollon 482
EC, Brennan D, et al. Child life specialist integration in ED 483
pain management. *Acad Emerg Med*. 2023;30:15–24.
484 <https://doi.org/10.1111/acem.14422>
485
- 486 26. Matula ST, Irving SY, Steenhoff AP, Polomano RC, Deatrick 486
JA. Parental education in pediatric pain management. *Pain 487
Manag Nurs*. 2019;20:236–43. [https://doi.org/10.1016/j.
488 pmn.2018.11.006](https://doi.org/10.1016/j.pmn.2018.11.006) 489
- 490 27. Yörükoğlu HU, Aksu C, Yucal NN, Cesur S, Kuş A. Regional 490
anesthesia in children: safety and outcomes. *Br J 491
Anaesth*. 2024;133:55–64. [https://doi.org/10.1016/j.
492 bja.2024.02.009](https://doi.org/10.1016/j.bja.2024.02.009) 493
- 494 28. Maisat W, Yuki K. Pediatric opioid safety: codeine and 494
tramadol contraindications. *Pediatrics*. 2024;153(2):7.
495 <https://doi.org/10.1542/peds.2022-059076>
496
- 497 29. Amashta ML, Barnes DK. Failsafe medication processes in 497
pediatric ED. *Jt Comm J Qual Patient Saf*. 2022;48:471–9.
498 <https://doi.org/10.1016/j.jcjq.2022.05.008>
499
- 500 30. Murthi S, Martini N, Falconer N, Scahill S. EHR integration 500
for pediatric analgesia safety. *J Am Med Inf Assoc*.
501 2023;30:876–84. [https://doi.org/10.1093/jamia/
502 ocab307](https://doi.org/10.1093/jamia/ocab307) 503
- 504 31. Bell J, Condren M. Language strategies for procedural 504
comfort in pediatrics. *J Pediatr Nurs*. 2021;58:27–34.
505 <https://doi.org/10.1016/j.pedn.2021.01.014>
506

- 507 32. Wilson-Smith EM. Developmental interventions for
508 procedural pain in infants. *CMAJ*. 2023;195(12):E405–13.
509 <https://doi.org/10.1503/cmaj.221707>
- 510 33. Williams S, Keogh S, Douglas C. Improving paediatric
511 pain management in the emergency department: an
512 integrative literature review. *Int J Nurs Stud*. 2019;94:9–
513 20. <https://doi.org/10.1016/j.ijnurstu.2019.02.017>
- 514 34. Morrison SN, Sigman L. Dignity and shared decision-
515 making in pediatric emergency care. *Pediatrics*.
516 2022;149:e2021054822. [https://doi.org/10.1542/](https://doi.org/10.1542/peds.2021-054822)
517 [peds.2021-054822](https://doi.org/10.1542/peds.2021-054822)
- 518 35. Ali S, McGrath T, Drendel AL. An evidence-based
519 approach to minimizing acute procedural pain in the
520 emergency department and beyond. *Pediatr Emerg*
521 *Care*. 2016;32:36–42. [https://doi.org/10.1097/](https://doi.org/10.1097/PEC.0000000000000669)
522 [PEC.0000000000000669](https://doi.org/10.1097/PEC.0000000000000669)
- 523 36. Goyal MK, Kuppermann N, Cleary SD, Teach SJ,
524 Chamberlain JM. Disparities in pediatric pain treatment.
525 *Pain Rep*. 2020;5:828. [https://doi.org/10.1097/](https://doi.org/10.1097/PR9.0000000000000828)
526 [PR9.0000000000000828](https://doi.org/10.1097/PR9.0000000000000828)
- 527 37. Herd DW, Babl FE, Gilhotra Y, Huckson S. Emergency
528 physicians' analgesic practices for pediatric patients.
529 *Emerg Med Australas*. 2024;36(2):214–21. [https://doi.](https://doi.org/10.1111/1742-6723.14038)
530 [org/10.1111/1742-6723.14038](https://doi.org/10.1111/1742-6723.14038)
- 531 38. Yee MM, Josephson C, Hill CE, Harrington R, Castillejo
532 MI, Ramjit R, et al. CYP2D6 polymorphism and opioid
533 response in children: a review. *Clin Pharmacol Ther*.
534 2023;113:224–36. <https://doi.org/10.1002/cpt.2777>
- 535 39. Gerards M, Miller J, Doshi D, Hoyer A, Flöttmann N,
536 Barthlen W. Virtual reality distraction reduces procedural
537 pain in children. *J Pediatr Nurs*. 2025;73:84–90. [https://](https://doi.org/10.1016/j.pedn.2024.12.011)
538 doi.org/10.1016/j.pedn.2024.12.011